Quick Facts

• Primary Use: Management of the symptoms associated with stable angina pectoris.
• Therapeutic Goal: Works to reduce the occurrence and severity of angina episodes.
• Benefit: May assist in improving exercise tolerance in patients with chronic stable angina.

---

Isangina is a prescription medication utilized in the therapeutic management of chronic stable angina, a condition involving chest discomfort. The primary use of this drug is to help manage and control the symptoms related to stable angina episodes, which typically occur when the heart muscle requires more oxygen than the coronary arteries can provide.

The medication is designed to support the overall goal of therapy, which is to lessen the frequency and intensity of discomfort. By helping to manage these episodes, Isangina may assist appropriate patients in improving their capacity for physical activity or exertion. It is an approved component of a comprehensive treatment strategy for stable angina, often used in conjunction with lifestyle adjustments and other medical interventions to help improve the patient's quality of life.

Regulatory References

1. NIH MedlinePlus guidance

Isangina (Isosorbide Mononitrate) is approved for use in the adult population for the prophylaxis of chronic stable angina. Regulatory documentation strictly defines eligibility by listing specific groups for whom the medicine is contraindicated and those for whom use is restricted.

Contraindicated Populations

Use of Isangina is strictly prohibited in patients with a known hypersensitivity to nitrates or the product's excipients. It must not be used concurrently with Phosphodiesterase type-5 (PDE-5) inhibitors (such as sildenafil or tadalafil) or riociguat. The medication is also contraindicated in the presence of marked hypotension (systolic blood pressure typically below 90 mmHg), acute circulatory failure, cardiogenic shock, and severe anaemia.

Age-Related Eligibility

The safety and efficacy have not been established in the pediatric population, and its use in children is not recommended. For the elderly, no routine dosage adjustment is required, but special care may be needed due to increased susceptibility to hypotension.

Conditional Use

Caution is required for patients with severe liver or renal disease and for those who are volume depleted. During pregnancy and lactation, use is restricted and should occur only if the physician deems the benefit essential and justifiable against potential risks.

Interactions with other medicines and products

Isangina (Isosorbide Mononitrate) has an officially documented interaction profile centered on the risk of profound pharmacodynamic amplification of its primary effect. The use of Isangina is contraindicated with two primary classes of medicinal products: Phosphodiesterase Type 5 (PDE5) Inhibitors (e.g., Sildenafil, Tadalafil) and Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat). This absolute prohibition is documented in regulatory labeling due to the potential for severe, life-threatening drops in blood pressure and associated cardiovascular complications.

Interaction is also documented with other antihypertensive agents, including beta-blockers, calcium channel blockers, and other vasodilators. Co-administration of these medicines may result in additive hypotensive effects, increasing the potential for marked symptomatic orthostatic hypotension. Furthermore, official documentation notes that Isangina may increase the blood level of certain Ergot-type medications (e.g., Dihydroergotamine).

Although co-administration with PDE5 Inhibitors is prohibited, mandatory separation times are specified in regulatory sources for emergency administration: the last dose of Sildenafil must have occurred at least 24 hours prior, and the last dose of Tadalafil at least 48 hours prior. Separately, consumption of alcohol (ethanol) is noted to accentuate the vasodilating effects of the medicine. Official documents state that consuming food does not significantly alter the overall extent of Isosorbide Mononitrate absorption.

Myocardial Oxygen Efficiency

This domain centers on Isangina's action as a selective inhibitor of mitochondrial fatty acid beta-oxidation within heart muscle cells. By limiting the heart's reliance on fatty acids as fuel, the drug promotes a metabolic shift, increasing the cell's reliance on glucose oxidation for generating adenosine triphosphate (ATP). The physiological consequence of this mechanism is an increase in the heart muscle's ATP production per unit of oxygen available, contributing to a greater output of ATP per unit of oxygen consumed.

Cardiac Ion Regulation

Isangina's mechanism also extends to modulating the critical balance of ions, primarily sodium (Na^+) and calcium (Ca^2+), inside the heart muscle cells. This activity modulates Ca^2+ handling, which influences the duration of the heart cycle's relaxation phase. This action influences the cellular Ca^2+ cycling dynamics necessary for muscle contraction and relaxation.

How Isangina is Used: Official Administration Guidelines

Isangina, whose active ingredient is Isosorbide Mononitrate (ISMN), is utilized through the oral route exclusively, available as both Immediate-Release (IR) tablets and Extended-Release (ER) tablets. The manner in which it is administered is specifically designed to adhere to a fixed-time schedule to maintain its effectiveness over time.

---

Official Dosing and Scheduling

The fundamental usage principle requires establishing a daily nitrate-free interval to minimize the risk of developing tolerance to the medication.

Formulation	Standard Dosing Regimen	Frequency and Timing	Special Constraints
Immediate-Release (IR)	Starting doses range from 5 mg to 20 mg twice daily, increasing to a maximum maintenance dose of up to 120 mg daily in divided doses.	Twice daily, with the two doses taken 7 hours apart (e.g., 8 a.m. and 3 p.m.) to create the nitrate-free period.	Doses may be taken with or without food, though some labels specify taking them on an empty stomach.
Extended-Release (ER)	Starting doses are typically 30 mg or 60 mg once daily. The dose may be adjusted up to a maximum of 240 mg once daily.	Once daily, usually upon arising in the morning, which naturally allows for a long nitrate-free interval overnight.	ER tablets must be swallowed whole with a liquid and must not be crushed, chewed, or split.

---

Procedural Administration Rules

Treatment with Isangina is intended for long-term use. For specific populations, official guidelines advise starting older adults at the low end of the dosing range. For all patients, treatment should not be stopped suddenly; the dosage and frequency must be tapered gradually to conclude the therapeutic course. Efficacy and safety have not been established in pediatric patients.

Research Evidence / Overview of Studies for Isangina

---

Evidence for Use in Chronic Stable Angina

The core research examining Isangina has focused on its evaluation in adults who have chronic stable angina. These studies were primarily Randomized Controlled Trials (RCTs), where patients were randomly assigned to receive Isangina or a placebo, often while continuing other standard medications. This design was used to explore how symptoms change over time.

Study Design and Measured Outcomes

Researchers designed these studies to monitor patient-reported outcomes related to episodic or acute changes, such as the frequency of angina episodes and the use of short-acting nitrate medication. Other key outcomes monitored included measuring changes in exercise tolerance time during treadmill tests over short treatment periods (typically 4 to 12 weeks). Studies also included high-level monitoring and reporting of adverse events (general safety patterns) over the study duration.

Findings from these short-term studies describe patterns measured in the studies. Specifically, research observed a pattern where the frequency of angina episodes reported by patients in the Isangina group was measured as lower compared to the placebo group. The data describe observations related to the measured outcomes. Similarly, some studies included measurements of exercise tolerance time for comparison between the Isangina and placebo study groups. These findings help contextualize how patients reported their experience during the study.

---

Long-Term Studies and Follow-Up Data

Research describes that the observed changes in symptoms over the short term were the primary focus of the initial evidence base. The research so far notes that while longer-term safety was monitored, data related to major cardiovascular events (like heart attack or cardiovascular death) over many years of use remain limited.

---

Evidence in Specific Patient Groups (Special Populations)

Data for patients with severe impairments in kidney or liver function are limited, as these patients were often excluded from the main efficacy trials. Similarly, data for children, adolescents, or women who are pregnant or breastfeeding are generally lacking. Results apply only to the populations studied.

---

What Is Still Uncertain About Isangina Research

Research provides context but not individual predictions. One limitation is that the reported findings describe changes that were measured over short periods, and findings describe group patterns, not personal outcomes. Data are still emerging for some specific endpoints, and comparative evidence is lacking against all other existing therapies.

Common questions about Isangina (FAQ)

Q: Where can I find the official prescribing information for Isangina?

A: Official prescribing information for medicines like Isangina (Isosorbide Mononitrate) is published by government regulatory agencies. You can find the U.S. labeling in the FDA DailyMed database or the European labeling via the European Medicines Agency (EMA) website. This information details the approved uses, safety, and proper administration of the medicine.

Q: What is the risk of having a serious allergic reaction to Isangina?

A: The official product information states that Isangina is absolutely prohibited (contraindicated) if a patient has a known allergy or hypersensitivity to the drug or any of its components. While severe allergic reactions to medicines in this class are documented as rare, regulatory guidance suggests patients discuss all known allergies with their healthcare provider prior to use.

Q: Is Isangina a controlled substance?

A: Regulatory information indicates that Isangina (Isosorbide Mononitrate) is a prescription-only drug (Rx). It is not currently classified or listed as a controlled substance under the U.S. Drug Enforcement Administration (DEA) scheduling system.

Q: Does Isangina make you feel tired or drowsy?

A: Commonly reported effects listed in official documents include dizziness, light-headedness, and a feeling of weakness or tiredness (fatigue). Because of these potential effects, it is often suggested that activities requiring alertness, such as driving or operating machinery, be approached with caution until the effects of the medicine are understood.

Q: If I miss a dose of Isangina, what is the usual recommendation?

A: Official patient information often describes the general approach: if a dose is missed, it may be taken as soon as the patient remembers. This approach changes if a long period of time has passed (such as eight hours or more), in which case the missed dose is usually skipped. Regulatory labeling consistently advises against taking a double dose to make up for a single missed dose.

Q: How long do the effects of one dose of Isangina last?

A: The sustained-release formulation of Isangina is designed to provide effects over an extended period. This design facilitates the schedule needed to maintain the medicine's effectiveness and prevent the development of drug tolerance.

Q: How is Isangina eliminated from the body?

A: Official pharmacokinetics data show that Isangina is primarily processed by the body through two pathways: denitration and glucuronidation. This process converts the active ingredient into inactive metabolites that are then mainly eliminated via the urine, with less than 1% of the original dose being removed unchanged.

Q: Does Isangina interact with herbal supplements?

A: There is not always enough regulatory information to definitively confirm the safety of all complementary medicines or herbal remedies when taken with Isangina. For this reason, official sources note that patients should discuss all supplements being used with their healthcare provider.

Q: Is it necessary to have routine monitoring while taking Isangina?

A: Regulatory clinical guidelines state that routine laboratory monitoring is not generally required for adjusting the dosage of this medicine. However, monitoring of blood pressure and heart rate is common practice, particularly when treatment begins or when the dosage is being adjusted.

Q: Is Isangina available as a generic medicine?

A: Yes, the active ingredient in Isangina, Isosorbide Mononitrate, is widely available as a generic medicine. Generic versions of the active ingredient are manufactured to meet the same official standards for quality and content as the brand-name product.

The storage and disposal of Isangina (Isosorbide Mononitrate) must strictly adhere to regulatory requirements to ensure product quality and public safety.

Storage Requirements

Condition	Official Requirement
Temperature	Store at controlled room temperature (15 C to 30 C or 59 F to 86 F).
Protection	Keep away from heat, moisture, and direct light. The product must not be frozen.
Container	Keep the tablets in their original container and ensure it is tightly closed.
Safety	Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Isangina must be discarded according to local and governmental regulations for pharmaceutical waste. Individuals should consult a pharmacist or healthcare professional on the proper disposal procedure for any unused medicine. Do not flush the tablets down the toilet or pour them down a drain unless specifically instructed by regulatory guidelines, as this can lead to environmental contamination.